pfm medical has closed the financial year 2015 (1 January to 31 December 2015) with a 7 per cent increase in sales over the previous year. The group achieved 102.1 million euros revenue in 2015 compared to 95.4 million euros in 2014. With the development of a long-term strategy concept, the group has set the course for the next five years. Due to investment in this strategy and some one-off special effects, the company’s earnings before interest and taxes (EBIT) of 4.1 million euros fell below those of the previous year (9.6 million euros). The workforce increased from 434 to 512 employees (as per 31.12.2015).
“In 2015, we have set the course for our future growth. At the expense of our profits, we have invested in the development of a sustainable long-term strategy”, Aurel Schoeller, Chairman of the Management Board and CEO of pfm medical ag comments the development over the reporting period. “We want to maintain our strong position as a medium-sized, family-owned company. This is the only way we will continue to be able to respond quickly to changing market conditions, for example due to digitalization or new legislation. This explains our high investments in the modernisation and extension of the production facilities at our site in Nonnweiler and in our IT systems, as well as the significant increase in our workforce.” pfm medical intends to pursue long-term strategies and stay on course regardless of short-term fluctuations in earnings, he added.
Growth on a broad scale
The 7 per cent growth in sales was achieved in all segments of products and services. The proportion of products manufactured in-house has increased to just over 50%. The group’s international business continued unchanged. This means that the share of international revenue lies just below 44% of the total revenue. Apart from a relatively high investment of more than one million euros in strategic development, factors causing the decline in profits were the strong devaluation of the Argentine peso and the increased personnel costs.
pfm medical reached the following milestones in 2015:
Development of the strategy concept up to 2021 in close partnership with a management consultancydevelopment of the LimLess infusion pump in-house for use in pain therapy and parenteral nutritionthe 12 months-data of the TiLOOP Total 6 study - conducted with 300 female patients and layed out for a period of 36 months - confirmed that the TiLOOP implant for pelvic floor reconstruction significantly improved the women’s quality of life following surgeryWith pfm medical tec, pfm medical ag established a subsidiary to produce high-precision appliances for histological laboratories such as microtomes for cutting tissue samples. Thereby, pfm medical offers product development, manufacturing, after-sales service and user training in a one-stop-shop.
Strategy concept for long-term corporate success
The supplier of medical products and services has already taken first steps to implement its new strategy: pfm medical has developed numerous projects which consistently promote the group as a supplier of comprehensive solutions, including both products and services as well as improving customers’ processes. Main indication fields are surgery, histotechnology, infusion and cardiovascular therapies.
“Apart from solid growth due to our sound business model, our high equity ratio also provides a reliable basis for further strategic development of our group”, explains Dr. Florian Dannheim, CFO of pfm medical ag. “Our finances are rock solid, and consequently we are well positioned to respond to our customers’ future demands as required”, Dannheim emphasizes his positive outlook.
Opportunities in the growth market of healthcare
The family-owned medical products group aims to expand its range of products and services across all sectors in its core market Germany. The further internationalisation of the business, the stronger concentration on indications and the enhancement of the solution and service portfolio are the focus of pfm medical. In these areas the course has been set, including the scalability of the company’s internal systems and processes as well as production capacities.
------------------------
Short profile
pfm medical ranks among the leading German companies in the field of medical technology and services. The Cologne-based family company was founded in 1971, and has more than 500 employees at twelve locations around the world. In 2015, pfm medical realized an EBIT (earnings before interest and taxes) of 4.1 million euros from 102.1 million euros in revenue. The medical products supplier has registered more than 80 patents, utility models and trademarks. As a specialist supplier of 3,100 products, the company offers an extensive portfolio which is distributed in more than 100 markets.
Its product range covers the four application fields infusion (e.g. infusion pumps and implantable port catheters), histotechnology (e.g. microtom blades and laboratory appliances), cardiovascular technologies (e.g. occlusion implants for congenital heart defects) and surgery (e.g. drainage systems and mesh implants).
pfm medical integrates products and services into a comprehensive solutions package. For instance, the company provides training and advice to physicians, nursing staff, patients and their families to ensure the best possible therapy outcomes in both inpatient and outpatient healthcare. In the development of innovative solutions in close cooperation with leading physicians and specialist partners, pfm medical invariably focuses on improvements in the quality of work and the quality of life for both users and patients.
Contact
pfm medical ag Ute Ebers Head of Corporate Communications Wankelstraße 60 50996 Köln T +49 (0)2236 9641-370 F +49 (0)2236 9641-99-370 ute.ebers[at]pfmmedical[dot]com
↧